Vitrolife AB

Vitrolife AB

10.25
USD
+0.75
(+7.84%)
-3.83EPS
1.16BMarket Cap
Jan 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.76
5.33
6.94
8.23
10.06
11.07
14.23
11.97
15.3
24.92
27.06
27.81
26.5
26.56
Basic EPS, GAAP
0.59
1.14
1.76
1.83
2.53
2.98
3.68
2.76
3.1
3.04
-29.68
3.95
-38.62
-38.29
Free Cash Flow per Basic Share
1.03
1.43
1.64
1.61
2.9
1.63
3.14
3.23
2.92
4.23
4.92
5.43
2.99
5.11
Dividend per Share
0.13
0.21
0.32
0.5
0.55
0.78
0.89
- -
0.8
0.85
0.89
1.04
1.15
1.15
Book Value per Share
3.3
6.74
8.1
9.79
11.78
14.35
17.24
19.34
118.03
128.92
98
105.06
60.81
63.82
Tangible Book Value per Share
1.13
1.34
3.15
3.55
5.94
7.35
9.76
12.59
-17.15
-13.76
-9.1
-6.35
-2.96
-1.98
Basic Weighted Avg Shares
95
96
104
104
104
104
104
104
110
130
130
130
130
129
Sales/Revenue/Turnover
453
511
722
856
1,046
1,151
1,480
1,246
1,681
3,234
3,512
3,609
3,440
3,439
Operating Margin (%)
17.41
26.61
28.87
28.97
32.82
33.79
32.98
30.17
25.46
20.01
21.01
21.95
16.69
-137.89
Depreciation Expense
35
23
53
54
67
85
99
84
109
396
425
442
427
- -
Net Income, GAAP
56
109
183
190
264
310
383
287
341
394
-3,851
513
-5,012
-4,957
Effective Tax Rate (%)
28.94
25.49
19.17
23.19
22.38
22.05
22.09
21.39
25.22
26.63
- -
23.74
- -
- -
Profit Margin (%)
12.43
21.37
25.31
22.24
25.2
26.9
25.86
23.03
20.29
12.18
-109.65
14.21
-145.7
-144.14
Working Capital
88
149
283
317
575
698
948
1,237
453
951
1,357
1,652
1,477
1,644
LT Debt
22
60
36
- -
- -
- -
61
49
2,026
2,043
1,942
1,929
1,562
1,678
Total Equity
316
703
845
1,020
1,229
1,496
1,798
2,017
15,341
16,740
12,723
13,641
7,895
8,118
Return on Invested Capital (%)
15.64
18.06
20.98
19.05
22.77
22.22
22.24
14.6
3.27
2.61
- -
3.9
- -
- -
Return on Capital (%)
16.14
19.16
21.81
19.49
23
22.68
22.76
14.54
3.47
2.32
- -
3.82
- -
- -
Return on Common Equity (%)
19.02
21.5
23.68
20.46
23.5
22.78
23.29
15.07
3.93
2.46
-26.15
3.89
-46.55
- -

Capital Structure

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
46
45
47
LT Borrowings
1,453
1,474
1,603
LT Finance Leases
83
82
75
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
130
130
127
Market Capitalization
13,096
13,033
11,554

Working Capital

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,179
2,199
2,257
Cash, Cash Equivalents & STI
886
823
860
Accounts Receivable, Net
665
716
772
Inventories
428
440
447
Total Current Liabilities
592
604
613
Payables & Accruals
- -
- -
- -
ST Debt
46
45
47
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.61%
122.16%
-42.12%
Free Cash Flow
17.82%
9.64%
-44.96%
Net Income, GAAP
-217.47%
-446.66%
-1,077%
Sales/Revenue/Turnover
19.75%
26.81%
-4.68%
Total Cash Common Dividend
- -
- -
10.37%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
841
941
867
959
3,609
2025
842
871
- -
891
3,440
2026
807
857
884
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.89
1.1
0.89
1.07
3.95
2025
0.77
0.77
- -
-40.94
-38.62
2026
0.78
0.99
0.99
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.04
- -
- -
1.04
2025
- -
1.15
- -
- -
1.15
2026
- -
1.15
- -
- -
- -

Company Description

CEO
Rickard Ericsson
Full Time Employees
1,151
Sector
Health technology
Industry
Medical specialties
Address
Gustaf Werners gata 2 Gothenburg VG Sweden 421 32
IPO Date
Jun 19, 2001
Business
Vitrolife AB (publ) Vitrolife AB (publ) develops, manufactures and commercializes medical devices and genetic testing services for assisted reproduction technologies and reproductive health clinics worldwide; its core offerings encompass IVF media and consumables including sperm processing solutions, oocyte retrieval needles, micromanipulation pipettes, dishes, tubes and embryo handling tools; time-lapse incubation and imaging systems such as EmbryoScope with integrated evaluation software; laser systems for embryo manipulation; cryopreservation equipment including VitroTemp; and genetic testing services via its Igenomix subsidiary covering preimplantation genetic testing for aneuploidy, structural rearrangements and monogenic disorders. The company operates through three main geographic segments—EMEA, Americas and APAC—with primary revenue from EMEA; it serves IVF clinics, fertility centers and reproductive health providers targeting patients seeking fertility treatments. Founded in 1994 and headquartered in Gothenburg, Sweden, Vitrolife supports the full IVF workflow from gamete preparation and fertilization through embryo culture, evaluation, transfer and cryopreservation, emphasizing quality control, regulatory compliance including CE marking and FDA clearance, and sustainability initiatives like ISO 14001 certification at its production facilities. In recent developments, Vitrolife completed the acquisition of eFertility (STB Zorg B.V.) in 2024, integrating its witnessing system and electronic medical records platform to advance digitalization and standardization across IVF workflows as part of a five-year strategy for end-to-end solutions; the company also renewed a EUR 300 million loan agreement comprising term loans and revolving credit facilities to bolster financial flexibility. Q3 2025 sales grew 5% organically, driven by consumables performance amid resilient demand in Americas and EMEA regions, while Q2 2025 reported flat growth in local currencies with 3% organic expansion excluding discontinued operations. These moves enhance Vitrolife's portfolio in automation, innovation and global scalability within the reproductive health sector.

Company News

  • Vitrolife AB (publ) (VTRLY) Q3 2026 Earnings Call Transcript

  • Vitrolife AB (publ) (OTCMKTS:VTRLY) Stock Price Up 7.8% – Should You Buy?

  • Vitrolife AB (publ) (VTRLY) Q2 2026 Earnings Call Transcript

  • Report from the Annual General Meeting of Vitrolife AB (publ)

  • Vitrolife AB (publ) (VTRLY) Q1 2026 Earnings Call Transcript

  • Vitrolife AB (publ) - Interim report Q1, 2026: Strong growth in Consumables and Technologies

  • Notice of the Annual General Meeting of Vitrolife AB (publ)

  • Vitrolife AB (publ) (VTRLY) Q4 2025 Earnings Call Transcript

  • Vitrolife AB (publ) - Fourth quarter and full year report 2025

  • Vitrolife AB (publ) (OTCMKTS:VTRLY) Shares Up 1.6% – Here’s What Happened

  • Vitrolife AB (publ) (OTCMKTS:VTRLY) Stock Price Down 16.4% – Should You Sell?

  • Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026